| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 6. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | paliperidone palmitate (Trevicta®) |
| Formulation | 175 mg, 263 mg , 350 mg and 525 mg |
| Reference number | 1318 |
| Indication | Maintenance treatment of schizophrenia in adult patients who are clinically stable on 1-monthly paliperidone palmiate injectable product |
| Company | Janssen-Cilag Ltd |
| BNF chapter | Central nervous system |
| Assessment type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 28/04/2016 |